More Than 450 Companies Drive Speed to Market with Veeva RIM
Veeva Systems (NYSE:VEEV) announced significant adoption of its Regulatory Information Management (RIM) platform, now used by over 450 companies, including 19 of the top 20 biopharmas. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance multi-health authority platform integration.
The platform's continuous publishing feature through Veeva Submissions Publishing is being utilized by more than 85 organizations to accelerate submission timelines. Accumulus's network connects over 70 regulatory agencies worldwide, while DNAnexus integration aims to improve inter-agency collaboration for faster product approvals.
Veeva Systems (NYSE:VEEV) ha comunicato una significativa adozione della sua piattaforma Regulatory Information Management (RIM), ora impiegata da oltre 450 aziende, compresa la maggior parte delle top 20 biopharma (19 su 20). L'azienda ha stretto partnership strategiche con Accumulus Technologies e DNAnexus per potenziare l'integrazione della piattaforma tra più autorità sanitarie.
La funzione di pubblicazione continua tramite Veeva Submissions Publishing è utilizzata da oltre 85 organizzazioni per accelerare i tempi di sottomissione. La rete di Accumulus collega più di 70 agenzie regolatorie nel mondo, mentre l'integrazione con DNAnexus punta a migliorare la collaborazione inter-agenzia per ottenere approvazioni di prodotto più rapide.
Veeva Systems (NYSE:VEEV) anunció una adopción significativa de su plataforma Regulatory Information Management (RIM), que ya utiliza más de 450 empresas, incluidas 19 de las 20 principales biofarmacéuticas. La compañía ha establecido alianzas estratégicas con Accumulus Technologies y DNAnexus para mejorar la integración de la plataforma entre múltiples autoridades sanitarias.
La función de publicación continua mediante Veeva Submissions Publishing está siendo empleada por más de 85 organizaciones para acelerar los plazos de presentación. La red de Accumulus conecta a más de 70 agencias regulatorias en todo el mundo, mientras que la integración con DNAnexus busca potenciar la colaboración entre agencias para acelerar las aprobaciones de productos.
Veeva Systems (NYSE:VEEV)는 자사의 규제 정보 관리(RIM) 플랫폼이 크게 확산되어 현재 450개 이상 기업에서 사용 중이며 상위 20개 바이오제약사 중 19곳이 포함된다고 발표했습니다. 회사는 Accumulus Technologies 및 DNAnexus와 전략적 파트너십을 체결해 다기관 보건 규제 당국 간 플랫폼 통합을 강화하고 있습니다.
Veeva Submissions Publishing을 통한 연속 게시 기능은 85개 이상의 조직에서 제출 일정을 단축하기 위해 활용되고 있습니다. Accumulus의 네트워크는 전 세계 70개 이상의 규제 기관을 연결하며, DNAnexus 통합은 기관 간 협업을 개선해 제품 승인 속도를 높이는 것을 목표로 합니다.
Veeva Systems (NYSE:VEEV) a annoncé une adoption significative de sa plateforme Regulatory Information Management (RIM), désormais utilisée par plus de 450 entreprises, dont 19 des 20 premières biopharmas. L'entreprise a noué des partenariats stratégiques avec Accumulus Technologies et DNAnexus pour renforcer l'intégration de la plateforme entre plusieurs autorités sanitaires.
La fonctionnalité de publication continue via Veeva Submissions Publishing est utilisée par plus de 85 organisations pour accélérer les délais de soumission. Le réseau d'Accumulus relie plus de 70 agences réglementaires dans le monde, tandis que l'intégration avec DNAnexus vise à améliorer la collaboration inter-agences pour des approbations de produits plus rapides.
Veeva Systems (NYSE:VEEV) gab bekannt, dass seine Regulatory Information Management (RIM)-Plattform nun umfangreich eingeführt ist und von über 450 Unternehmen genutzt wird, darunter 19 der Top-20-Biopharmaunternehmen. Das Unternehmen hat strategische Partnerschaften mit Accumulus Technologies und DNAnexus geschlossen, um die plattformübergreifende Integration zwischen mehreren Gesundheitsbehörden zu verbessern.
Die fortlaufende Veröffentlichungsfunktion über Veeva Submissions Publishing wird von mehr als 85 Organisationen genutzt, um Einreichungszeiten zu beschleunigen. Das Netzwerk von Accumulus verbindet über 70 Zulassungsbehörden weltweit, während die DNAnexus-Integration die Zusammenarbeit zwischen Behörden verbessern und damit Produktzulassungen beschleunigen soll.
- Strong market adoption with over 450 companies using Veeva RIM, including 19 of top 20 biopharmas
- Strategic partnerships with Accumulus Technologies and DNAnexus enhance platform capabilities
- 85+ organizations using continuous publishing feature for improved efficiency
- Access to Accumulus's network of 70+ regulatory agencies worldwide
- None.
Insights
Veeva's RIM platform reaches 450 customers including top biopharmas, expanding market dominance through strategic partnerships and enhanced capabilities.
Veeva Systems has achieved a significant milestone with its Regulatory Information Management (RIM) platform now being used by more than 450 companies, including 19 of the top 20 biopharma organizations. This level of adoption demonstrates Veeva's continued dominance in the life sciences regulatory technology space.
The announcement highlights two strategic partnerships that strengthen Veeva's ecosystem: Accumulus Technologies, which connects to over 70 regulatory agencies worldwide, and DNAnexus, which offers Trusted Regulatory Spaces for data sharing. These integrations create a powerful network effect that reinforces Veeva's platform value proposition while addressing a critical pain point in regulatory submissions - connectivity with health authorities.
Veeva's continuous publishing functionality, now used by over 85 organizations, represents an important operational efficiency gain for pharmaceutical companies by reducing rework and bottlenecks in the submission process. This directly impacts speed-to-market for new treatments, a crucial competitive advantage in the pharmaceutical industry.
As part of Veeva's broader Development Cloud ecosystem, the RIM platform benefits from integration across clinical, quality, regulatory, and safety functions. This unified approach offers customers significant operational efficiencies compared to managing these functions through disparate systems.
The continued expansion of Veeva's regulatory platform solidifies their position as the leading provider of cloud solutions for life sciences regulatory affairs, enhancing their recurring revenue streams and competitive moat in this specialized enterprise software category.
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities
"Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, Veeva RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment," said Marc Gabriel, vice president, regulatory at Veeva.
Companies using Veeva RIM applications can streamline processes across all steps of the regulatory lifecycle. With Veeva Submissions Publishing, more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.
"Our strategic partnership will connect the Accumulus platform and Veeva RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster," said Francisco Nogueira, CEO of Accumulus Technologies.
"Integrating DNAnexus Trusted Regulatory Spaces (TRS) and Veeva RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals," said Thomas Laur, CEO of DNAnexus.
Veeva RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about Veeva RIM, visit veeva.com/RIM.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Elizabeth McGrane
Veeva Systems
elizabeth.mcgrane@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542568.html
SOURCE Veeva Systems
FAQ
How many companies are currently using Veeva RIM platform?
What new partnerships has Veeva Systems (VEEV) announced for RIM platform?
How many organizations use Veeva Submissions Publishing for continuous publishing?
What is the reach of Accumulus Technologies' regulatory network for Veeva RIM users?
What is Veeva RIM's role in the Veeva Development Cloud?
